About
12.93USD+0.15 +1.17%
Closed • Updated at 22:40 GMT+00:00Market Cap$1.08B
Volume783.9K
Beta2.15
RSI46.45
Gross Margin56.51%
Eyepoint, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
May 14 2026
EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data
May 6 2026
EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments
Apr 29 2026
EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026
Mar 4 2026
EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments
Mar 2 2026
EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema
Community Chat
Ask AI
Try asking
Google Übersetzer